MaxCyte, Inc. (LON:MXCT) Insider John Johnston Sells 118 Shares

Posted by on Aug 1st, 2023

MaxCyte, Inc. (LON:MXCT – Get Free Report) insider John Johnston sold 118 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of GBX 480 ($6.16), for a total transaction of £566.40 ($727.18).

MaxCyte Price Performance

MXCT stock opened at GBX 355 ($4.56) on Tuesday. The stock has a market capitalization of £365.83 million, a P/E ratio of -1,552.17 and a beta of 0.74. The company has a debt-to-equity ratio of 6.56, a quick ratio of 14.38 and a current ratio of 14.81. MaxCyte, Inc. has a one year low of GBX 291.35 ($3.74) and a one year high of GBX 650 ($8.35). The company has a 50 day moving average price of GBX 357.91 and a two-hundred day moving average price of GBX 381.64.

About MaxCyte

(Get Free Report)

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Featured Articles

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.